Page 6
If approved by the European Commission, enzalutamide will be the only oral therapy for the treatment of metastatic hormone-sensitive prostate cancer in addition to non-metastatic and metastatic castration-resistant…
HSE-Medicines Management Programme (MMP) has completed an evaluation to identify preferred blood glucose test strips (BGTS) for adults with type 1 and type 2 diabetes mellitus, as part…
Grünenthal Pharma Limited are pleased to announce the completion of the transfer of the marketing authorisation for Vimovo (naproxen 500mg / esomeprazole 20mg) to Grünenthal Pharma Limited on…
Servier Laboratories (Ireland) Ltd are delighted to announce that Lipercosyl®, the combination of atorvastatin and perindopril, will be available for prescription from February 2021 and is listed as…
Accord Healthcare is delighted to announce the launch of another Hi-Tech medicine to their already extensive range of Hi Tech medicines, Ambrisentan Accord 5 & 10 mg which…
Exergen Corporation, a global leader in infrared temperature measurement technologies for medical applications, announced today that Oxygen Care has supplied 22 Intensive Care Units in Ireland with highly…
Phase 2b dose-finding study showed that delgocitinib cream demonstrated a statistically significant dose-response relationship compared with vehicle in adults with mild-to-severe chronic hand eczema, the most common skin…
Consilient Health Ltd. is pleased to announce the launch of Altavita D3 50,000 iu (Colecalciferol) capsules for the treatment of vitamin D deficiency. The recommended dose is one…
XELJANZ 11mg prolonged-release tablets provide RA patients a once-daily dosing option Pfizer Healthcare Ireland has today announced the availability of XELJANZ® (tofacitinib citrate) 11mg prolonged-release tablets for the once-daily…
Digital Health: Clinical Study Published in “Ophthalmology” Demonstrates Implandata’s EYEMATE System Benefits Glaucoma Patients HANNOVER, Germany, July 27, 2020 / B3C newswire / — People suffering from glaucoma…
You’re all caught up.
